JBCHEPHARM Latest Share Price (JBCHEPHARM)
TODAY IN ONE LINE
With a market cap of ₹38,730.77 Cr., it trades at a P/E of 54.59. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
JBCHEPHARM flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 17.1% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 16.7%
- ●Healthy Operating MarginsOPM is structurally strong at 23.3%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●FII AccumulationFII holding increased by 1.45% QoQ
- ●Promoter BuyingPromoters increased holdings by 48.80% QoQ
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 31.0% YoY
- ●Sales ContractionQuarterly sales dropped 7.5% YoY
- ●Expensive ValuationTrading at a high P/E ratio of 51.9x
- ●Promoter Pledging DetectedPledge activity recorded on 27-May-2025
Latest JBCHEPHARM News
What changed recently?
Recent events, corporate actions, and announcements.
JBCHEPHARM valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for JBCHEPHARM, framed against the sector median so the premium or discount is obvious at a glance.
JBCHEPHARM trades at a P/E of 54.59× and P/B of 9.31×, against the Healthcare sector median P/E of 41.12×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
JBCHEPHARM technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for JBCHEPHARM — derived from the latest tape, not yesterday's close.
JBCHEPHARM last traded at ₹2,408.9 with an intraday range of ₹2,380–₹2,525.5 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹2408.90| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2787.27 | +378.37 | +15.71% |
| R3 | 2641.77 | +232.87 | +9.67% |
| R2 | 2583.63 | +174.73 | +7.25% |
| R1 | 2496.27 | +87.37 | +3.63% |
| PIVOT | 2438.13 | 29.23 | 1.21% |
| CURRENT | 2408.90 | — | — |
| S1 | 2350.77 | -58.13 | -2.41% |
| S2 | 2292.63 | -116.27 | -4.83% |
| S3 | 2205.27 | -203.63 | -8.45% |
| S4 | 2059.77 | -349.13 | -14.49% |
JBCHEPHARM is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹–₹
Trading Below opening range, showing Bearishness
JBCHEPHARM financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for JBCHEPHARM — consolidated or standalone — with margins, YoY growth and key ratios inline.
JBCHEPHARM reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹38,730.77 Cr. and reported EPS of ₹6.01.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 3,918 | 4,148 ▲ 5.9% |
| Sales Growth YoY %Derived | 12.45% | 5.87% |
| Other Income | 38 | 60 ▲ 57.0% |
| Total Income | 3,956 | 4,208 ▲ 6.4% |
| 1,317 | 1,296 ▼ 1.5% | |
| Gross ProfitDerived | 2,601 | 2,852 ▲ 9.6% |
| Gross Margin %Derived | 66.40% | 68.75% |
| 1,570 | 1,744 ▲ 11.1% | |
| EBITDA (Operating Profit)Derived | 1,032 | 1,107 ▲ 7.3% |
| OPM %Derived | 26.34% | 26.70% |
| 183 | 161 ▼ 12.0% | |
| Profit Before Tax (PBT) | 887 | 952 ▲ 7.3% |
| 228 | 243 ▲ 6.6% | |
| Effective Tax %Derived | 25.67% | 25.50% |
| Total Profit for Period | 660 | 709 ▲ 7.6% |
| Less: Non-controlling Interests | — | — |
| Net Profit (Owner's PAT)Derived | 660 | 709 ▲ 7.6% |
| Net Profit Margin %Derived | 16.83% | 17.10% |
| PAT Growth YoY %Derived | 19.35% | 7.56% |
| Earnings Per Share (EPS ₹) | 42.37 | 44.19 ▲ 4.3% |
| Diluted Shares Outstanding (Cr) | 16 | 16 ▲ 3.1% |
| Other Comprehensive Income (Net of Tax) | 9 | 27 ▲ 213.3% |
| Total Expenses (incl. D&A & Interest) | 3,069 | 3,256 ▲ 6.1% |
| Material Cost % of RevenueDerived | 20.93% | 22.00% |
| Employee Cost % of RevenueDerived | 17.55% | 18.63% |
| Other Cost % of RevenueDerived | 22.51% | 23.42% |
| Interest Coverage (x)Derived | 73.38x | 166.06x |
| Period | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,414 | 1,643 ▲ 16.2% | 1,775 ▲ 8.0% | 2,043 ▲ 15.1% | 2,424 ▲ 18.7% | 3,149 ▲ 29.9% | 3,484 ▲ 10.6% | 3,918 ▲ 12.5% | 4,148 ▲ 5.9% | |
| Sales Growth YoY %Derived | — | 16.25% | 8.00% | 15.09% | 18.69% | 29.91% | 10.63% | 12.45% | 5.87% | |
| Other Income | 37 | 41 ▲ 13.3% | 51 ▲ 22.3% | 112 ▲ 121.8% | 39 ▼ 65.1% | 10 ▼ 74.7% | 37 ▲ 274.9% | 38 ▲ 2.8% | 60 ▲ 57.0% | |
| Total Income | 1,450 | 1,685 ▲ 16.2% | 1,825 ▲ 8.4% | 2,155 ▲ 18.1% | 2,463 ▲ 14.3% | 3,159 ▲ 28.2% | 3,521 ▲ 11.5% | 3,956 ▲ 12.3% | 4,208 ▲ 6.4% | |
538 | 596 ▲ 10.9% | 631 ▲ 5.8% | 701 ▲ 11.2% | 843 ▲ 20.2% | 1,168 ▲ 38.6% | 1,182 ▲ 1.2% | 1,317 ▲ 11.4% | 1,296 ▼ 1.5% | ||
| Gross ProfitDerived | 876 | 1,047 ▲ 19.5% | 1,144 ▲ 9.3% | 1,341 ▲ 17.2% | 1,581 ▲ 17.9% | 1,981 ▲ 25.3% | 2,302 ▲ 16.2% | 2,601 ▲ 13.0% | 2,852 ▲ 9.6% | |
| Gross Margin %Derived | 61.95% | 63.70% | 64.46% | 65.66% | 65.23% | 62.91% | 66.07% | 66.40% | 68.75% | |
658 | 741 ▲ 12.7% | 766 ▲ 3.4% | 781 ▲ 1.9% | 1,038 ▲ 33.0% | 1,285 ▲ 23.8% | 1,405 ▲ 9.3% | 1,570 ▲ 11.7% | 1,744 ▲ 11.1% | ||
| EBITDA (Operating Profit)Derived | 218 | 305 ▲ 40.2% | 378 ▲ 23.6% | 560 ▲ 48.4% | 543 ▼ 3.0% | 696 ▲ 28.0% | 897 ▲ 28.9% | 1,032 ▲ 15.0% | 1,107 ▲ 7.3% | |
| OPM %Derived | 15.41% | 18.59% | 21.28% | 27.44% | 22.42% | 22.09% | 25.74% | 26.34% | 26.70% | |
60 | 60 ▼ 1.0% | 59 ▼ 0.8% | 76 ▲ 27.9% | 78 ▲ 2.5% | 150 ▲ 93.4% | 183 ▲ 21.4% | 183 ▲ 0.1% | 161 ▼ 12.0% | ||
| Profit Before Tax (PBT) | 194 | 287 ▲ 48.0% | 349 ▲ 21.6% | 597 ▲ 71.1% | 505 ▼ 15.4% | 555 ▲ 10.0% | 752 ▲ 35.4% | 887 ▲ 18.1% | 952 ▲ 7.3% | |
55 | 93 ▲ 68.4% | 77 ▼ 17.8% | 148 ▲ 93.9% | 119 ▼ 19.9% | 145 ▲ 22.2% | 199 ▲ 36.9% | 228 ▲ 14.5% | 243 ▲ 6.6% | ||
| Effective Tax %Derived | 28.48% | 32.41% | 21.93% | 24.86% | 23.54% | 26.16% | 26.46% | 25.67% | 25.50% | |
| Total Profit for Period | 139 | 194 ▲ 39.8% | 272 ▲ 40.4% | 449 ▲ 64.7% | 386 ▼ 13.9% | 410 ▲ 6.2% | 553 ▲ 34.8% | 660 ▲ 19.4% | 709 ▲ 7.6% | |
| Less: Non-controlling Interests | 0 | — ▼ 100.0% | 0 | 1 ▲ 62.1% | 1 ▲ 21.8% | 0 ▼ 75.1% | — ▼ 100.0% | — | — | |
| Net Profit (Owner's PAT)Derived | 138 | 194 ▲ 40.2% | 272 ▲ 40.3% | 448 ▲ 64.7% | 385 ▼ 14.0% | 410 ▲ 6.4% | 553 ▲ 34.8% | 660 ▲ 19.4% | 709 ▲ 7.6% | |
| Net Profit Margin %Derived | 9.79% | 11.80% | 15.33% | 21.93% | 15.90% | 13.01% | 15.86% | 16.83% | 17.10% | |
| PAT Growth YoY %Derived | — | 40.21% | 40.25% | 64.66% | -13.98% | 6.35% | 34.84% | 19.35% | 7.56% | |
| Earnings Per Share (EPS ₹) | 8.25 | 12.09 ▲ 46.5% | 17.60 ▲ 45.6% | 28.98 ▲ 64.7% | 24.93 ▼ 14.0% | 26.48 ▲ 6.2% | 35.61 ▲ 34.5% | 42.37 ▲ 19.0% | 44.19 ▲ 4.3% | |
| Diluted Shares Outstanding (Cr) | 17 | 16 ▼ 4.0% | 15 ▼ 3.7% | 15 ▲ 0.0% | 15 ▲ 0.0% | 15 ▲ 0.1% | 16 ▲ 0.3% | 16 ▲ 0.3% | 16 ▲ 3.1% | |
| Other Comprehensive Income (Net of Tax) | -0 | -4 ▼ 966.2% | -15 ▼ 256.9% | 0 ▲ 102.2% | 4 ▲ 1097.3% | -14 ▼ 439.0% | -15 ▼ 7.7% | 9 ▲ 158.4% | 27 ▲ 213.3% | |
| Total Expenses (incl. D&A & Interest) | 1,256 | 1,398 ▲ 11.3% | 1,477 ▲ 5.6% | 1,558 ▲ 5.5% | 1,959 ▲ 25.7% | 2,604 ▲ 33.0% | 2,770 ▲ 6.4% | 3,069 ▲ 10.8% | 3,256 ▲ 6.1% | |
| Material Cost % of RevenueDerived | 27.38% | 27.61% | 25.50% | 26.55% | 24.84% | 24.89% | 23.43% | 20.93% | 22.00% | |
| Employee Cost % of RevenueDerived | 17.76% | 17.54% | 18.20% | 16.68% | 18.12% | 17.26% | 17.26% | 17.55% | 18.63% | |
| Other Cost % of RevenueDerived | 28.78% | 27.58% | 24.99% | 21.54% | 24.69% | 23.56% | 23.07% | 22.51% | 23.42% | |
| Interest Coverage (x)Derived | 46.07x | 59.49x | 102.74x | 67.91x | 91.94x | 16.13x | 17.11x | 73.38x | 166.06x |
JBCHEPHARM segment analysis : revenue and profit mix.
Disclosed business segments at JBCHEPHARM with their share of revenue and profit, switchable between consolidated and standalone reporting.
JBCHEPHARM discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for JBCHEPHARM.
Our AI distills the core fundamental drivers supporting JBCHEPHARM, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
JBCHEPHARM's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
Operating margin 22.10% significantly outpaces pharmaceutical peer benchmarks consistently.
Strong ROCE 25.40% and ROE 18.90% demonstrate efficient capital deployment.
Minimal debt burden with D/E ratio 0.0000 ensures robust financial flexibility.
Stable promoter holding 48.80% signals long-term management commitment and stability.
Positive operating cash flow ₹644.89 Cr in FY26 supports dividend sustainability.
Key Risks.
Latest quarterly EPS declined 30.4% YoY despite revenue growth momentum.
TTM EPS declined 31.0% YoY indicates significant earnings contraction.
P/E ratio 51.93 remains elevated versus peer median, limiting upside.
Dividend payout ratio 65.11% constrains reinvestment capacity for growth.
Stock price near 52-week high ₹2,509.40 with flat momentum signals limited near-term upside.
Flip Conditions.
Valuation risk. a P/E above 71 (~1.7× the sector multiple of 41.1) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 12% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.46%.
JBCHEPHARM peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — JBCHEPHARM is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
JBCHEPHARM chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for JBCHEPHARM — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
JBCHEPHARM delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for JBCHEPHARM over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in JBCHEPHARM stood at 66.8% of traded volume, against a 20-day average of 62.4%.
JBCHEPHARM announcements: results, concalls, ratings, M&A.
Filings JBCHEPHARM sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
JBCHEPHARM files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 158 documents below.
Suspension of Trading
Members of the Exchange are hereby informed that the trading in equity shares of JB Chemicals & Pharmaceuticals Limited shall be suspended w.e.f.…
General Updates
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about General Updates
Record Date
JB Chemicals & Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Merger/HiveOff is 17-Jul-2026.
General Updates
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about General Updates
General Updates
JB Chemicals & Pharmaceuticals Limited has informed the Exchange about General Updates
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
JBCHEPHARM dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue JBCHEPHARM has declared, sequenced by announce and record date.
JBCHEPHARM corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
JBCHEPHARM insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in JBCHEPHARM as reported to SEBI — buying and selling signals from the people who know the business best.
JBCHEPHARM insider activity below tracks 34 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Sujay Kamlakar Rajhans | Insider | 17 Mar 2026 | buy | +11.8 K | ₹2.49 Cr. | ₹2,110.00 |
| Sujay Kamlakar Rajhans | Insider | 17 Mar 2026 | buy | +11.8 K | ₹2.49 Cr. | ₹2,110.00 |
| Sujay Kamlakar Rajhans | Insider | 17 Mar 2026 | buy | +11.8 K | ₹2.49 Cr. | ₹2,110.00 |
| Sujay Kamlakar Rajhans | Insider | 17 Mar 2026 | buy | +11.8 K | ₹2.49 Cr. | ₹2,110.00 |
| Parmeshwar Bang | Insider | 12 Jun 2025 | buy | +1.1 K | ₹19.28 L | ₹1,752.73 |
| Vikas Khare | Insider | 12 Jun 2025 | sell | −950 | ₹16.66 L | ₹1,753.34 |
| Sandeep Phadnis | Insider | 12 Jun 2025 | sell | −1.0 K | ₹17.56 L | ₹1,755.62 |
| Parmeshwar Bang | Insider | 12 Jun 2025 | sell | −1.1 K | ₹19.28 L | ₹1,752.73 |
| Nikhil Ashokkumar Chopra | Insider | 11 Jun 2025 | buy | +50.0 K | ₹8.8 Cr. | ₹1,760.00 |
| Kunal Khanna | Insider | 11 Jun 2025 | buy | +21.1 K | ₹3.59 Cr. | ₹1,706.32 |
About JBCHEPHARM: business, sector, key facts.
What JBCHEPHARM does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
JBCHEPHARM operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: JBCHEPHARM, BSE: 506943.
J.B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM) is a prominent Indian pharmaceutical company engaged in the manufacture and marketing of a diverse range of pharmaceutical products both domestically and internationally. Their business model encompasses three core areas: pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (APIs).
A significant portion of JBCHEPHARM's business revolves around the production and sale of APIs, which are the fundamental building blocks of many pharmaceutical drugs. Their API portfolio is extensive and includes key ingredients for various therapeutic applications, such as diclofenac sodium, nifedipine, atenolol, ciprofloxacin, and cetirizine, amongst others. This allows them to control a key stage in the supply chain and provide components to other pharmaceutical companies, as well as use them internally.
Beyond APIs, JBCHEPHARM manufactures and markets a wide array of finished pharmaceutical formulations. These encompass various dosage forms designed to cater to a broad spectrum of therapeutic needs, including tablets, capsules, injectables, gels, creams, ointments, syrups, and lozenges. The company's product portfolio covers a comprehensive range of therapeutic areas, encompassing gastroenterology, anti-infectives, wound care, pediatrics, gynecology, dentistry, vitamins and minerals, hypertension, diabetes, nephrology, respiratory ailments, pain management, dermatology, antivirals, and contrast media for medical imaging.
In addition to their core pharmaceutical business, JBCHEPHARM also offers herbal remedies, expanding their product offerings to encompass traditional medicine. This diversification further strengthens their market position and caters to a broader consumer base. Furthermore, the company provides contract manufacturing services, leveraging its manufacturing capabilities to produce products for other companies in the pharmaceutical industry.
JBCHEPHARM's integrated approach, encompassing API manufacturing, formulation development, and contract manufacturing, positions it as a significant player within the Indian and international pharmaceutical markets. Their broad therapeutic coverage and diversified product portfolio contribute to their market success. The company’s long history, established in 1976, speaks to their resilience and adaptability within a constantly evolving industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week high (breakout watch)Screener
- Breakout Trader strategy playbookStrategy
- Top Losers TodayScreener
- Other overvalued NSE stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about JBCHEPHARM (JBCHEPHARM).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of JBCHEPHARM (JBCHEPHARM)?
The current share price of JBCHEPHARM (JBCHEPHARM) is ₹2,408.90. Today, the stock has declined by ₹97.10 (3.87%), trading in a range of ₹2,380.00 to ₹2,525.50. The stock opened at ₹2,506.00 with a trading volume of 47,79,224 shares.
02Is JBCHEPHARM stock a good investment for long-term?
JBCHEPHARM can be considered for long-term investment based on several factors. The company has a market capitalization of ₹38,730.77 Cr., P/E ratio of 54.59, ROE of 16.7%, and ROCE of 17.05%. The dividend yield stands at 0.91%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of JBCHEPHARM stock?
The 52-week high price of JBCHEPHARM (JBCHEPHARM) is ₹2,525.50, while the 52-week low is ₹1,638.50. Currently trading at ₹2,408.90, the stock is 47.02% above its 52-week low and 4.62% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy JBCHEPHARM stock at the current price?
Whether to buy JBCHEPHARM stock at ₹2,408.90 depends on multiple factors. The stock is currently trading with a P/E ratio of 54.59 and P/B ratio of 9.31. Today's performance shows a loss of 3.87%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of JBCHEPHARM and when is the next dividend?
JBCHEPHARM offers a dividend yield of 0.91%, which means for every ₹100 invested at the current price of ₹2,408.90, you can expect to receive approximately ₹0.91 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of JBCHEPHARM?
JBCHEPHARM's key financial metrics include: P/E Ratio: 54.59, P/B Ratio: 9.31, ROE: 16.7%, ROCE: 17.05%, Dividend Yield: 0.91%, EPS: ₹6.01, Book Value: ₹259.05, and Debt-to-Equity: 0. The company's market cap stands at ₹38,730.77 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is JBCHEPHARM stock performing today in the market?
JBCHEPHARM stock opened at ₹2,506.00 and is currently trading at ₹2,408.90, showing a decline of ₹97.10 (3.87%). The intraday high is ₹2,525.50 and low is ₹2,380.00. The trading volume stands at 47,79,224 shares, indicating strong market participation today.
08What is the P/E ratio of JBCHEPHARM and what does it indicate?
JBCHEPHARM has a Price-to-Earnings (P/E) ratio of 54.59, which means investors are willing to pay 54.59 for every ₹1 of earnings. With an EPS of ₹6.01, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about JBCHEPHARM (JBCHEPHARM) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.